Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7651 to 7665 of 8211 results

  1. Commercial access agreements

    The NICE commercial liaison team aim to reduce the workload for the NHS and frontline staff by making commercial agreements more straightforward.

  2. Past appeals and decisions

    Past technology appraisal appeals and decisions

  3. Research to access pathway for investigational drugs for COVID-19 (RAPID C-19)

    RAPID C-19’s role in reviewing potential COVID-19 treatments has now ended because we have moved back to routine commissioning arrangements for these treatments.

  4. Corporate publications

    NICE's business plan, annual report, charter, transformation story, gender pay gap report, framework agreement and other publications.

  5. NICE guidance implementation toolkits

    Home Implementing NICE guidance...

  6. Patient access schemes and pricing agreements

    Home What NICE does {"@context":"http://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"/"

  7. Compliance with nice-approved medicines or treatments

    Clarification on demonstrating patient access to medicines and treatments recommended by NICE Technology Appraisal (TA) or Highly Specialised Technologies (HST) guidance.

  8. Highly specialised technologies evaluation committee members

    Biographies for each member of the highly specialised technologies evaluation committee.

  9. Technology appraisal committee D members

    Find out more about NICE technology appraisals advisory committee D members

  10. Up to 6,000 people set to benefit after NICE recommends new life-extending drug for advanced prostate cancer

    People living with metastatic prostate cancer in England will gain access to a new treatment combination from today (Friday, 24 October), following a recommendation by NICE.

    News
    Last updated
    24 October 2025

  11. Prioritisation board decisions 2024

    Our centralised approach to prioritising guidance topics ensures that we produce guidance that is relevant, timely, accessible, and has demonstrable impact.

  12. Our prioritisation decisions

    NICE's decisions on how we prioritise topics, by year.

  13. Shaping the future of global health technology assessment

    Learn about our role in the new international Health Economics Methods Advisory (HEMA) and its ambitions to make a real difference to patients around the world.

    News
    Last updated
    24 October 2025

  14. About quality standards

    Our quality standards set out priority areas for quality improvement in health, public health and social care.

  15. Artificial intelligence (AI) and digital regulations service

    We're playing a leading role in the AI and digital regulations service which supports the development and adoption of AI and data-driven technologies in health and care.